For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the acute pharyngitis industry by 2029?
The acute pharyngitis market size has grown strongly in recent years. It will grow from $2.67 billion in 2024 to $2.90 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing incidence of viral and bacterial infections, growing healthcare awareness, advancements in diagnostic technologies, rising number of pediatric cases, increase in environmental pollutants and allergens.
The acute pharyngitis market size is expected to see rapid growth in the next few years. It will grow to $3.98 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rising prevalence of influenza and streptococcal infections, increased focus on personalized medicine, growing adoption of rapid diagnostic tests, improvements in healthcare infrastructure, expanding access to healthcare in emerging markets. Major trends in the forecast period include shift towards over-the-counter treatments, increase in use of combination therapies, growth in telemedicine for pharyngitis diagnosis, rise of natural and alternative remedies, increasing preference for self-care and home-based treatments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21082&type=smp
Which industry-specific innovations are acting as key drivers for the acute pharyngitis market?
Rise in prevalence of influenza is expected to propel the growth of the acute pharyngitis market going forward. Influenza is attributed to infection with influenza viruses, which spread through respiratory droplets from coughs, sneezes, or contact with contaminated surfaces. The rise in prevalence of influenza is due to factors such as seasonal variations, low vaccination rates, increased human mobility, viral mutations, and weakened immunity in certain populations. Acute pharyngitis treatment helps influenza patients by alleviating throat inflammation and pain, reducing discomfort while swallowing, preventing secondary bacterial infections, and supporting overall recovery, which, when combined with antiviral medications, adequate hydration, and rest, enhances the body’s ability to fight the influenza virus more effectively. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, as of February 2025, the percentage of clinical lab tests that were positive for influenza reached 31.6%, up from 29.4% the previous week and 18.6% at the start of the year. Thus, the rise in prevalence of influenza is driving the growth of the acute pharyngitis market.
Which segment currently leads the acute pharyngitis market in terms of revenue share?
The acute pharyngitis market covered in this report is segmented –
1) By Treatment: Antibiotics, Antivirals, Over-the-Counter (OTC) Medications, Corticosteroids And Anti-inflammatory Drugs, Alternative Remedies
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By End-User: Hospitals, Homecare, Speciality Centres, Other End Users
Subsegments:
1) By Antibiotics: Penicillins, Cephalosporins, Macrolides
2) By Antivirals: Neuraminidase Inhibitors, Nucleoside Analogs
3) By Over-the-Counter (OTC) Medications: Analgesics, Throat Lozenges, Cough Syrups
4) By Corticosteroids And Anti-inflammatory Drugs: Glucocorticoids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5) By Alternative Remedies: Herbal Teas, Honey-Based Solutions, Saltwater Gargles
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/acute-pharyngitis-global-market-report
What future trends will impact the direction of the acute pharyngitis industry?
Major companies operating in the acute pharyngitis market are focusing on developing antibiotics to combat bacterial infections more effectively and reduce antibiotic resistance. Antibiotics are crucial in treating acute pharyngitis caused by bacterial infections, such as streptococcus pyogenes, by eliminating the bacteria, reducing symptoms, and preventing complications such as rheumatic fever. For instance, in February 2022, Alembic Pharmaceuticals Limited, an India-based pharmaceutical company, received Abbreviated New Drug Application (ANDA) approval for Clarithromycin tablets USP, 250 mg and 500 mg from Food & Drug Administration (USFDA), a US-based government agency. This macrolide antibiotic is used to treat mild to moderate bacterial infections, including pharyngitis or tonsillitis, community-acquired pneumonia, and chronic bronchitis. The approval underscores the importance of effective antimicrobial treatments in managing acute pharyngitis and related bacterial infections.
Who are the top competitors in the global acute pharyngitis market?
Major companies operating in the acute pharyngitis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Glaxo Smithkline Pharmaceuticals Ltd, F. Hoffmann-La Roche AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz Group AG, Bitop AG, Hikma Pharmaceuticals, Lupin Limited, Alkem Laboratories Ltd., MEDICE Arzneimittel Pütter GmbH & Co. KG, MCM Klosterfrau Vertriebsgesellschaft mbH
What regional dynamics are shaping the future of the global acute pharyngitis market?
North America was the largest region in the acute pharyngitis market in 2024. The regions covered in the acute pharyngitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Acute Pharyngitis Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21082
Need Customized Data On Acute Pharyngitis Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21082&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
